Liquidia Corp (LQDA) Stock Analysis
Verdict: WATCH (do not buy)
Yutrepia commercial scale is overshadowed by severe legal overhangs and sudden stock collapse — risk-reward hinges on patent resolution.
Investment score: 42/100
Analysis as of
Is Liquidia Corp stock worth reviewing? AI model thesis
The model score of 42/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Liquidia Corp opportunities and risks
What speaks for LQDA
- Rapid YUTREPIA commercial ramp demonstrating high market adoption.
What speaks against LQDA
- Binary legal and patent litigation exposure against United Therapeutics.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| LQDA | 19.3x | 6.0x | 14.3x | 92.5% | 30.7% | 2.2% |
| ELAN | n/a | 2.2x | 18.8x | 52.6% | -4.0% | 3.4% |
| AXSM | n/a | 12.2x | n/a | 93.2% | -24.7% | -0.8% |
| BLTE | n/a | 0.0x | n/a | 0.0% | 0.0% | -0.0% |
| AMRX | 40.5x | 2.1x | 13.9x | 39.3% | 5.0% | 1.3% |
| LGND | 31.2x | 21.5x | 23.3x | 98.6% | 67.9% | 2.1% |
| Peer median | n/a | 2.2x | 13.9x | 52.6% | 0.0% | 1.3% |
Frequently asked questions about Liquidia Corp (LQDA)
Is LQDA stock a good investment?
The cached TradeMates AI model rates Liquidia Corp as WATCH (do not buy) with an investment score of 42/100. The model score of 42/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is LQDA stock a buy?
The TradeMates model verdict for LQDA is WATCH (do not buy) with an investment score of 42/100. Treat this as a model signal to review, not a personal buy recommendation.